BACE1 and Alzheimer disease: To maximize the beneficial effect of the composite therapy for symptomatic conventional AD and to minimize its potential detrimental consequences, the administration of both types of drugs, namely inhibitors of the ISR and activators of BACE1 and/or BACE2, should be carefully coordinated.